Moderna, Merck's skin cancer vaccine shows sustained benefit after five years

Core Insights - Moderna and Merck announced that their experimental vaccine for a serious type of skin cancer, when used in combination with Keytruda, demonstrated a 49% reduction in the risk of recurrence or death in a mid-stage trial [1] Company Summary - The collaboration between Moderna and Merck focuses on developing a vaccine targeting a serious skin cancer [1] - The mid-stage trial results indicate significant efficacy, suggesting potential for further development and commercialization [1] Industry Summary - The findings contribute to the ongoing advancements in cancer immunotherapy, particularly in the context of skin cancer treatment [1] - The combination of the experimental vaccine with Keytruda highlights the trend of using combination therapies to enhance treatment outcomes in oncology [1]